Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
HOUSTON, May 04, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 11, 2017 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2017, and to provide a business overview.
To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time, and refer to conference ID 11686674. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
